SEC Form 4 · accession 0001562180-18-005050

REGENXBIO Inc. · RGNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Dec 17, 2018

Accepted (ET)

Dec 19, 2018 · 4:20 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001590877

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Dec 17, 2018	S	7,604	$46.11	D	223,396	D
Common Stock^F3	Dec 17, 2018	S	2,988	$46.81	D	220,408	D
Common Stock^F4	Dec 17, 2018	S	4,408	$47.74	D	216,000	D

No Table II lines on this filing.

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2This transaction was executed in multiple trades at prices ranging from $45.43 to $46.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $46.44 to $47.435. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $47.44 to $48.125. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.